Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pancreatic Cancer AND Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    518 result(s) found for: Pancreatic Cancer AND Cancer. Displaying page 9 of 26.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2005-000590-21 Sponsor Protocol Number: FFC33-24 Start Date*: 2005-08-24
    Sponsor Name:Faustus Forschung Compagnie, Translational Cancer Research GmbH
    Full Title: A Phase II Study of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)-urea (HECNU) in pancreatic cancer
    Medical condition: Pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002574-36 Sponsor Protocol Number: PRODIGE35 Start Date*: 2014-08-20
    Sponsor Name:Fédération Francophone de Cancérologie Digestive
    Full Title: Phase II randomized study evaluation of FOLFIRINOX +/- LV5FU2 in maintenance and FIRGEM in 1rst line of metastatic pancreas cancer
    Medical condition: metastatic pancreas adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10033575 Pancreas cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-001500-18 Sponsor Protocol Number: 1403-0011 Start Date*: 2022-11-07
    Sponsor Name:Boehringer Ingelheim España S.A.
    Full Title: Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract ade...
    Medical condition: cancer in the biliary tract or pancreas
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028982 Neoplasm biliary tract LLT
    20.0 100000004864 10033575 Pancreas cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Trial now transitioned) NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002386-30 Sponsor Protocol Number: 33-04 Start Date*: 2015-02-20
    Sponsor Name:Verein für Krebsforschung
    Full Title: Efficacy and Safety of Mistletoe Extract in the Palliative Therapy of Patients Suffering from Pancreatic Cancer (PALM-Pan)
    Medical condition: Locally advanced or metastatic adenocarcinoma of the pancreas (UICC stadium III or IV)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-000216-29 Sponsor Protocol Number: NL68762.078.19 Start Date*: 2019-08-07
    Sponsor Name:Erasmus MC
    Full Title: Safety and efficacy of the addition of IMM-101 Heat-Killed Whole Cell Mycobacterium obuense to standard stereotactic radiotherapy in locally advanced pancreatic cancer patients (LAPC-2 trial).
    Medical condition: Locally advanced pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-003751-37 Sponsor Protocol Number: BO21128 Start Date*: 2008-05-29
    Sponsor Name:F. Hoffmann-La Roche
    Full Title: A Phase II, Dose-Escalation to rash Trial of Erlotinib (Tarceva®) plus Gemcitabine in Patients With Metastatic Pancreatic Cancer.
    Medical condition: Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) IT (Completed) AT (Completed) DE (Completed) GB (Completed) LT (Completed) GR (Completed) ES (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2011-003715-28 Sponsor Protocol Number: HALO-109-201 Start Date*: 2011-12-08
    Sponsor Name:Halozyme, Inc.
    Full Title: A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined with PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Compared to Gemcitabine...
    Medical condition: Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002852-34 Sponsor Protocol Number: S61508 Start Date*: 2020-02-10
    Sponsor Name:UZLeuven
    Full Title: Progression-free Survival after Minimally Invasive Surgical Microwave Ablation plus Durvalumab (MEDI4736) and Tremelimumab for Unresectable Non-metastatic Locally Advanced Pancreatic Cancer. MIMIPA...
    Medical condition: Unresectable Locally Advanced Non Metastatic Pancreatic Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000423-12 Sponsor Protocol Number: CP506-001 Start Date*: 2022-12-13
    Sponsor Name:Maastricht University
    Full Title: A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor agnostic ...
    Medical condition: Tumour Agnostic treatment. ● Module differentiation: – Module 1 - monotherapy – solid tumour patients with cancer types that are enriched for HRD/FAD defects – Module 2 – combination with Carboplat...
    Disease: Version SOC Term Classification Code Term Level
    24.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10084788 HRD positive advanced ovarian cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-021951-26 Sponsor Protocol Number: UoL000621/R&D3963 Start Date*: 2011-04-15
    Sponsor Name:University of Liverpool [...]
    1. University of Liverpool
    2. Royal Liverpool and Broadgreen University Hospitals Trust
    Full Title: VIP: A prospective, phase II, double blinded, multicentre, randomised clinical trial comparing combination gemcitabine and vandetanib therapy with gemcitabine therapy alone in locally advanced or m...
    Medical condition: Locally advanced or metastatic pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10033600 Pancreatic adenocarcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002196-34 Sponsor Protocol Number: Neo.Lu.Pa.NET Start Date*: 2019-11-07
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE Followed by Surgery for resectable Pancreatic Neuroendocrine Tumors (Neo.Lu.Pa.NET)
    Medical condition: Resectable pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000741-46 Sponsor Protocol Number: 2017/2523 Start Date*: 2017-10-06
    Sponsor Name:Gustave Roussy
    Full Title: RANDOMIZED PHASE 2 TRIAL OF TWO CHEMOTHERAPY REGIMENS PLUS OR MINUS BEVACIZUMAB IN PATIENTS WITH WELL DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS
    Medical condition: Pancreatic well differentiated neuroendocrine tumors (NET)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067518 Pancreatic neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003768-30 Sponsor Protocol Number: IEO906 Start Date*: 2019-11-12
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Neoadjuvant peptide receptor radionuclide therapy (PRRT) with 90Y-DOTATOC in pancreatic neuroendocrine tumors
    Medical condition: Pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005471-17 Sponsor Protocol Number: RASH Start Date*: 2012-05-08
    Sponsor Name:Klinikum der Universität München-Großhadern
    Full Title: Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factors
    Medical condition: metastatic pancreatic carcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10033576 Pancreas carcinoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004859-32 Sponsor Protocol Number: TTD-20-04 Start Date*: Information not available in EudraCT
    Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD)
    Full Title: Olaparib and durvalumab (MEDI4736) in patients with metastatic pancreatic cancer and DNA Damage Repair genes alterations
    Medical condition: Metastatic pancreatic cancer and DNA Damage Repair genes alterations
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001341-34 Sponsor Protocol Number: TCD6595 Start Date*: 2006-07-16
    Sponsor Name:Sanofi-aventis recherche & developpement
    Full Title: Open label, uncontrolled study of XRP9881 in combination with trastuzumab (Herceptin®) in patients with HER2 positive metastatic breast cancer (MBC)
    Medical condition: HER2 positive Metastatic Breast Cancer patients
    Disease: Version SOC Term Classification Code Term Level
    11.1 10033604 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003601-25 Sponsor Protocol Number: LipoGem-PII-1L-Pancr Start Date*: 2012-04-18
    Sponsor Name:Regulon AE
    Full Title: Randomised, Multicenter Phase III Clinical Study of Lipoplatin plus Gemcitabine Versus Gemcitabine as First-Line Treatment in Inoperable, Locally Advanced or Metastatic Pancreatic Cancer
    Medical condition: Patients with Inoperable, Locally Advanced or Metastatic Pancreatic Cancer, not previously treated with chemotherapy for the current disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prohibited by CA)
    Trial results: (No results available)
    EudraCT Number: 2022-001867-29 Sponsor Protocol Number: 1081HV Start Date*: 2022-11-02
    Sponsor Name:Amsterdam UMC
    Full Title: [68Ga]Ga-FAPI-46 positron emission tomography in pancreaticobiliary cancers: a pharmacokinetics, repeatability and diagnostic accuracy study.
    Medical condition: Pancreatic carcinoma and cholangiocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005774-37 Sponsor Protocol Number: GETNE-2016-01 Start Date*: 2016-04-29
    Sponsor Name:Grupo Español de Tumores Neuroendocrinos. SECRETARÍA TÉCNICA GETNE (GETNE)
    Full Title: Phase II study to evaluate efficacy of rechallenge with Sunitinib in Patients with Metastatic Pancreatic Neuroendocrine Tumor (pNETs) well differentiated G1/2 advanced or metastatic who previously ...
    Medical condition: Metastatic Pancreatic Neuroendocrine Tumor (pNETs) well differentiated G1/2 advanced or metastatic
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068909 Pancreatic neuroendocrine tumour metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000317-17 Sponsor Protocol Number: ICI20-00047 Start Date*: 2021-08-11
    Sponsor Name:Fundación para la Gestión de la Investigación Biomédica de Cádiz-INIBICA
    Full Title: Survival analysis after neoadjuvant therapy in patients with resectable pancreatic cancer and risk factors
    Medical condition: Resectable pancreatic cancer and risk factors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10033608 Pancreatic cancer resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 04 05:53:04 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA